north east working on cure .

Remdisiver case study was in university of chicago. of the 113 severe cases most have been discharged 2 deaths. 

reports Univesity Of Chicago Medicine covid19 documuntation remdesiver report. 

there are currently 6 clinical studies after china declined phase 3 study.

NiAid Began global trials in february National Instute of Alergergy

Giliad is running phase three and 4 clinicals in highest infection rate.

world wide as studies in korea asia europe and united states continue to measure treatment standards.

Bought Moderna on April 3 for a little over 30 bucks. $46 today. I'm pleased but am unsure of when to get out. Not now for sure, but soon. I hope they come up with the vaccine for everyone's sake. 

You are up over 50% in 2 weeks!  Don't forget to press the sell button...

i thinking the crest will be about 65.00 but not sure.

Moderna with mrna1273 covid vaccine trials. 

Clinical trials .gov/ct2/show/NCT04283461 

they are recruiting in Emory Vaccine Center. The hope clinic.

Dacatuer , GA 30030-1075

Kaiser permemente washington health research institute. 

vaccine and infectious diseases.

National Institute of Health Clinic Center

Vaccine research center Vaccine Trials Program.

Bethsda, Maryland.20892

Central contact for these programs are handled by NIAID

KPWA.vaccine@kp.org.

Moderna has started dosing the first participants in all age cohorts of the Phase II clinical trial of its Covid-19 vaccine candidate, mRNA-1273.

mRNA-1273 is an mRNA vaccine encoding for a prefusion stabilised form of the Spike (S) protein, which was chosen by the company in alliance with Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID).

The Phase II trial will assess the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 administered 28 days apart. It is set to involve 600 healthy participants across the age groups of 18-55 and 55 and above.

Participants will receive either a 50µg dose, a 100µg dose, or placebo at both vaccinations and will be followed for 12 months after the second vaccination.

In the Phase I trial of the vaccine candidate, 25µg and 100µg dose levels demonstrated neutralising antibody titers at or above convalescent sera and were observed to be generally well-tolerated.

Moderna has decided to drop the assessment of the 250µg dose in the Phase II trial.

The US Food and Drug Administration (FDA) completed a review of the company’s investigational new drug (IND) application for the vaccine candidate on 6 May and granted fast track designation on 12 May.

Moderna stock is currently worth 58. It crested at 81. And has fallen back a bit.